PipelineReview.com7h
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant ...
PipelineReview.com7h
SPARC announces submission of IND Application for SBO-154 to USFDA
“SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.” said Anil ...